Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1040

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 1040
---
 by Dr. Charbel Moussa, MBBS,Ph.D. The study is expected
to start in the third quarter of 2025 and have results available approximately 12 months thereafter.

We are also targeting the treatment of MCI/early
Alzheimer’s Disease. We received funding of $2.2 million from the National Institute of Aging (“NIA”) in in 2020 and
2022 from a grant application for a Phase 1 study for Mild Cognitive Impairment/ Alzheimer’. In the NIA scientific review summary
statement of our Phase I study application, it is stated that the NIA is looking forward to a Phase II study with an enhanced resveratrol
product, based on the earlier study results from the well published Turner et al. Alzheimer’s study. We presently have a pending
grant application, $16.5 Million, for a Phase II trial in MCI/early Alzheimer’s Disease with the NIA. This is an application for
a 3-year Phase II trial that is expected to be completed with approximately 100 patients that have Mild Cognitive Impairment. We expect a decision on this grant application in May 2025. There is no guarantee that the application will be approved, and the trial will be put on hold if an approval
is not awarded to the Company. A draft of the final study design is not yet determined but a draft synopsis is described in “Item
1. Business - “ of this Annual Report on Form 10-K.

83

We have recently entered into service agreements in
the areas of Business Development, CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management with
companies that has their main operation in Hong Kong. These agreements are with companies that, we believe, have the knowledge and network
in the South-East Asian market to accelerate steps that is needed to have a product that can have treatment value in the territory. The
agreements are further described in the section “Activities in Asia”.

In March 2025, the Company announced that it had entered
into a partnership with Aquanova AG to develop a series of nutritional products targeting longevity, aging and Healthspan. The first three
products, which will focus on the concept of “Beauty from Within”, are slated to hit the market in the third quarter of 2025
through a Direct-to-Consumer model. The Company will form a wholly-owned subsidiary to focus on the consumer market, and will market its
products on a to-be-develop